Sustained Avastin aids colon cancer survival-study | Reuters. LOS ANGELES (Reuters) – Colorectal cancer patients who continued treatment with Roche Holding AG’s Avastin even after their cancer worsened lived longer than those who went off the drug, according to an “observational analysis” released on Thursday.